Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

465 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404).
Ganjoo K, Hong F, Horning SJ, Gascoyne RD, Natkunam Y, Swinnen LJ, Habermann TM, Kahl BS, Advani RH. Ganjoo K, et al. Among authors: habermann tm. Leuk Lymphoma. 2014 Apr;55(4):768-72. doi: 10.3109/10428194.2013.816700. Epub 2013 Jul 29. Leuk Lymphoma. 2014. PMID: 23786456 Free PMC article.
Bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine and prednisone (BLEO-CCVPP) in patients with Hodgkin's disease who relapsed after radiotherapy alone: a long-term follow-up study of the Eastern Cooperative Oncology Group (E3481).
Wiernik PH, Leong T, Oken MM, Neiman RS, Habermann TM, Bennett JM, Schuster S, Glick JH. Wiernik PH, et al. Among authors: habermann tm. Leuk Lymphoma. 2001 Jan;40(3-4):357-63. doi: 10.3109/10428190109057935. Leuk Lymphoma. 2001. PMID: 11426558 Clinical Trial.
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study.
Winter JN, Weller EA, Horning SJ, Krajewska M, Variakojis D, Habermann TM, Fisher RI, Kurtin PJ, Macon WR, Chhanabhai M, Felgar RE, Hsi ED, Medeiros LJ, Weick JK, Reed JC, Gascoyne RD. Winter JN, et al. Among authors: habermann tm. Blood. 2006 Jun 1;107(11):4207-13. doi: 10.1182/blood-2005-10-4222. Epub 2006 Jan 31. Blood. 2006. PMID: 16449523 Free PMC article. Clinical Trial.
A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.
Micallef IN, Kahl BS, Maurer MJ, Dogan A, Ansell SM, Colgan JP, Geyer S, Inwards DJ, White WL, Habermann TM. Micallef IN, et al. Among authors: habermann tm. Cancer. 2006 Dec 15;107(12):2826-32. doi: 10.1002/cncr.22342. Cancer. 2006. PMID: 17099879 Free article. Clinical Trial.
Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone.
Simpson L, Ansell SM, Colgan JP, Habermann TM, Inwards DJ, Ristow KM, Johnston PB, Markovic SN, Micallef IN, Porrata LF, Witzig TE. Simpson L, et al. Among authors: habermann tm. Leuk Lymphoma. 2007 Jul;48(7):1332-7. doi: 10.1080/10428190701435259. Leuk Lymphoma. 2007. PMID: 17613762
Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study.
Hochster H, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T, Zhang L, Colocci N, Frankel S, Horning SJ. Hochster H, et al. Among authors: habermann tm. J Clin Oncol. 2009 Apr 1;27(10):1607-14. doi: 10.1200/JCO.2008.17.1561. Epub 2009 Mar 2. J Clin Oncol. 2009. PMID: 19255334 Free PMC article. Clinical Trial.
465 results